UroGen Pharma

We’re excited to announce a long-term follow-up study to the OLYMPUS trial showing a median duration of response of four years in patients with low-grade upper tract urothelial cancer (LG-UTUC) were presented today at the Society for Urologic Oncology annual meeting. #SUO24     Learn more about the data: https://bit.ly/3Bgk1hp

Today we announced the presentation of long-term durability data from the Phase 3 ENVISION trial for patients with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC) at SUO 2024. Learn more: https://bit.ly/4ip9QYw

Real-world evidence (RWE) in urology has helped to inform urologists' understanding and treatment decisions.     As Dr. Yair Lotan, Professor of Urology at the University of Texas Southwestern Medical Center, explains, “There's value in looking at drugs post-approval and assessing how they're utilized and how the data holds up in the real-world.”     Be sure to tune into this week’s episode of The UroGist with Dr. Yair Lotan, Professor of Urology at the University of Texas Southwestern Medical Center and Michael Louie, MD MPH MSc, where they take a deeper dive into how RWE can inform outcomes in urology. Listen now on Spotify: https://bit.ly/3Yl8y7F or Apple Podcasts: https://bit.ly/3Uei6QX

We’re excited about the new data presentations on our innovative treatment in development for patients with low-grade, intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC) and our treatment for low-grade upper tract urothelial carcinoma (LG-UTUC) at the Society of Urologic Oncology 2024 Annual Meeting (SUO). #SUO24 Learn more about our presence at SUO: https://bit.ly/3Zhk8kJ

The Journal of Urology published new results from a long-term follow-up study evaluating our treatment for adult patients with low-grade, upper tract urothelial cancer (LG-UTUC). See the results: https://bit.ly/3CMdT0O

#ICYMI: Episode 2 of The UroGist is now available on Apple Podcasts and Spotify! Join Michael Louie, MD MPH MSc, and Jennifer Linehan, MD, as they explore how antegrade administration is used for treating patients with low-grade upper tract urothelial cancer (LG-UTUC). Don’t miss this insightful discussion!      Whether you’re a urologist or healthcare professional looking to deepen your understanding of LG-UTUC, this conversation offers valuable insights and discussion on real-world case studies you won’t want to miss.  Listen now on Spotify: https://bit.ly/3Yl8y7F or Apple Podcasts: https://bit.ly/3Uei6QX

#ICYMI – last week The UroGist launched! In the first episode, Michael Louie, MD MPH MSc and Dr. Katie Murray discuss our insights into treatment approaches for low-grade upper tract urothelial cancer patients, including, diagnosis and treatment challenges, and more.  Listen now on Spotify: https://bit.ly/3Yl8y7F or Apple Podcasts: https://bit.ly/3Uei6QX

We’re excited to connect with urologists and leading industry experts in #urology at the LUGPA Annual Meeting this week. We’ll be at booth 504 and look forward to the discussions on improving communication and supporting better clinical outcomes for patients. #LUGPA2024

Our new podcast, The UroGist, is streaming on Spotify and Apple Podcasts. If you want to be a part of an engaging virtual community that exchanges ideas and insights and tackles complexities surrounding urologic oncology, you’ve come to the right place. Check out our series on Spotify: https://bit.ly/3Yl8y7F or Apple Podcasts: https://bit.ly/3Uei6QX

Tomorrow, members of our management team will participate in a fireside chat during the Guggenheim Partners Securities Healthcare Conference. Register for the webcast: https://bit.ly/3UGBFRR